Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

By G. Folprecht, A. Grothey, S. Alberts, H. Raab, C. Köhne. Annals of Oncology, 2005

641 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients (2008, background): “For the substantial part of this series chemotherapy comprised 5 Fluorouracil based regimes which is well recognized as having minimal effect on long-term survival; median survival being in the order of 12 months.(34) In the past few years, newer chemotherapeutic regimes have been employed in some p”
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, background): “Furthermore, there is consistent evidence that by increasing the activity of chemotherapy, a greater proportion of patients can undergo a secondary surgery on metastases, and that this can allow long-term survival in a fraction of them.(13) On the basis of these data, several groups have developed t”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Resection rates have been shown to be correlated with response to systemic therapy [175].”